Cargando…
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study
BACKGROUND: Anthracycline‐based chemotherapy (ABC) is one of the standard therapies against breast cancer. However, few guidelines are currently available to optimize the use of ABC. Therefore, the present analysis aimed at determining the profile and treatment patterns of ABC and the association of...
Autores principales: | Guo, Fengzhu, Yi, Zongbi, Wang, Wenna, Han, Yiqun, Yu, Pei, Zhang, Su, Ouyang, Quchang, Yan, Min, Wang, Xiaojia, Hu, Xichun, Jiang, Zefei, Huang, Tao, Tong, Zhongsheng, Wang, Shusen, Yin, Yongmei, Li, Hui, Yang, Runxiang, Yang, Huawei, Teng, Yuee, Sun, Tao, Cai, Li, Li, Hongyuan, Chen, Xi, He, Jianjun, Liu, Xinlan, Yang, Shune, Fan, Jinhu, Qiao, Youlin, Wang, Jiayu, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495288/ https://www.ncbi.nlm.nih.gov/pubmed/34472719 http://dx.doi.org/10.1002/cam4.4215 |
Ejemplares similares
-
Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021) -
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy
por: Chen, Shanshan, et al.
Publicado: (2021) -
A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023) -
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
por: Xu, Binghe, et al.
Publicado: (2021) -
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)